What is Ochre Bio?
Headquartered in the heart of Oxford's innovation ecosystem, Ochre Bio is a pioneering biotechnology firm dedicated to the development of RNA-based therapeutics. By leveraging advanced deep phenotyping techniques, the company identifies novel biological pathways associated with chronic liver diseases. A core differentiator of their methodology involves the utilization of human livers maintained on perfusion machines, allowing for rigorous preclinical validation. This unique platform ensures that therapeutic candidates are optimized for clinical success, bridging the gap between genomic discovery and patient-centric outcomes.
How much funding has Ochre Bio raised?
Ochre Bio has raised a total of $39.6M across 2 funding rounds:
Angel/Seed
$9.6M
Series A
$30M
Angel/Seed (2021): $9.6M with participation from Backed, Apollo Health Ventures, Hoxton, Hermes-Epitek, Khosla Ventures, and Selvedge
Series A (2022): $30M led by Selvedge, Hermes-Epitek, Khosla Ventures Acquisition, Backed VC, and Lifeforce Capital Gp I
Key Investors in Ochre Bio
Apollo Health Ventures
A transatlantic early-stage venture capital firm focused on investing in transformative healthcare companies that address age-related diseases and aging.
Backed
A human-centric seed fund focused on supporting brave founders who are building generation-defining companies in frontier technology.
Hermes-Epitek
A specialized provider of semiconductor manufacturing and flat panel display process equipment, contributing to technological advancements through a comprehensive supply chain.
What's next for Ochre Bio?
The infusion of capital positions Ochre Bio to scale its operational capacity and advance its lead programs through the regulatory pipeline. As the company transitions from foundational research to clinical application, the focus will likely shift toward expanding its therapeutic portfolio and strengthening its intellectual property moat. By maintaining its commitment to rigorous scientific validation, Ochre Bio is well-positioned to disrupt the current standard of care for liver disease, potentially transforming patient outcomes through precision RNA medicine.
See full Ochre Bio company page
